Clinical Trial Update: Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating adding DKP21102_B to DKP21102_A for dyslipidemias was withdrawn and will not proceed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias

Drugs mentioned

• DKP21102_A
• DKP21102_B

Snippet

Sponsor: Dongkwang Pharm. Co., Ltd. | Conditions: Dyslipidemias | Phase 3 | Status: WITHDRAWN